Subcategory
Other indications (e.g. myeloproliferative diseases)
Trial Type
Follow-Up Treatment
Description for experts
This is an open-label, randomized (2:1), multicenter, Phase 3 study of imetelstat compared with BAT in approximately 320 participants with intermediate-2 or high-risk MF (primary MF [PMF], post-ET-MF [PET-MF], or post-PV-MF [PPV-MF]) who are refractory to JAK-inhibitor
treatment.
Description for laymen
This is an open-label, randomized (2:1), multicenter, Phase 3 study of imetelstat compared with BAT in approximately 320 participants with intermediate-2 or high-risk MF (primary MF [PMF], post-ET-MF [PET-MF], or post-PV-MF [PPV-MF]) who are refractory to JAK-inhibitor
treatment.
JSON Data
{
"short_title": "MYF3001",
"data_mode": "910",
"data_mode_number": "000000011",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "rezidiv_haema",
"ctgov_number": null,
"eudract_number": "2020-003288-24",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Dies ist eine offene, randomisierte (2:1), multizentrische Phase-3-Studie zu Imetelstat im Vergleich zu BAT bei etwa 320 Teilnehmern mit MF mit mittlerem oder hohem Risiko 2 (prim\u00e4re MF [PMF], Post-ET-MF [PET-MF] oder Post-PV-MF [PPV-MF]), die auf eine Behandlung mit JAK-Inhibitoren nicht ansprechen.",
"description_laie_en": "This is an open-label, randomized (2:1), multicenter, Phase 3 study of imetelstat compared with BAT in approximately 320 participants with intermediate-2 or high-risk MF (primary MF [PMF], post-ET-MF [PET-MF], or post-PV-MF [PPV-MF]) who are refractory to JAK-inhibitor \r\ntreatment.",
"description_expert_de": "Dies ist eine offene, randomisierte (2:1), multizentrische Phase-3-Studie zu Imetelstat im Vergleich zu BAT bei etwa 320 Teilnehmern mit MF mit mittlerem oder hohem Risiko 2 (prim\u00e4re MF [PMF], Post-ET-MF [PET-MF] oder Post-PV-MF [PPV-MF]), die auf eine Behandlung mit JAK-Inhibitoren nicht ansprechen.",
"description_expert_en": "This is an open-label, randomized (2:1), multicenter, Phase 3 study of imetelstat compared with BAT in approximately 320 participants with intermediate-2 or high-risk MF (primary MF [PMF], post-ET-MF [PET-MF], or post-PV-MF [PPV-MF]) who are refractory to JAK-inhibitor \r\ntreatment.",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 22
}
